Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group

BACKGROUND: Erwinia asparaginase is a Food and Drug Administration approved agent for the treatment of acute lymphoblastic leukemia (ALL) for patients who develop hypersensitivity to Escherichia coli derived asparaginases. Erwinia asparaginase is efficacious, but has a short half-life, requiring six...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Pediatr Blood Cancer
Päätekijät: Rau, Rachel E., Dreyer, ZoAnn, Choi, Mi Rim, Liang, Wei, Skowronski, Roman, Allamneni, Krishna P., Devidas, Meenakshi, Raetz, Elizabeth A., Adamson, Peter C., Blaney, Susan M., Loh, Mignon L, Hunger, Stephen P.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2017
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5839116/
https://ncbi.nlm.nih.gov/pubmed/29090524
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.26873
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia